ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$192.87 |
| 52 Week High | US$207.32 |
| 52 Week Low | US$153.58 |
| Beta | 0.56 |
| 1 Month Change | 12.42% |
| 3 Month Change | 15.99% |
| 1 Year Change | 8.67% |
| 3 Year Change | 33.91% |
| 5 Year Change | 103.11% |
| Change since IPO | 451.06% |
Recent News & Updates
AbbVie: An Undervalued Dividend Aristocrat
Feb 14AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
Jan 26Recent updates
AbbVie: An Undervalued Dividend Aristocrat
Feb 14AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
Jan 26AbbVie's Stock Is Unfairly Cheap
Jan 09AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
Jan 03
Betting Big On AbbVie: A Prescription For Growth And Dividends
Dec 11AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64
Dec 09AbbVie: Upgrading To 'Strong Buy' After Pullback
Nov 22AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64
Nov 19AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
Nov 12AbbVie Stock: Keep Calm And Buy The Dip
Nov 11AbbVie: 3 Positives From The Earnings Report
Oct 30AbbVie: Strong Dividends But Humira Disappoints
Oct 22AbbVie: Dividend Discount Model Suggests Large Valuation Risks
Sep 29We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt
Sep 06Why AbbVie Remains One Of My Favorite Dividend Growers
Aug 27AbbVie: Growth Is Still A Better Choice
Jul 29AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
Jul 17AbbVie: A Hold Again (Rating Downgrade)
Jul 03Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)
Jun 28Shareholder Returns
| ABBV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.2% | 0.4% | 1.5% |
| 1Y | 8.7% | -2.7% | 22.4% |
Return vs Industry: ABBV exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ABBV underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 55,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | US$340.48b |
| Earnings (TTM) | US$4.24b |
| Revenue (TTM) | US$56.33b |
80.3x
P/E Ratio6.0x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$56.33b |
| Cost of Revenue | US$16.73b |
| Gross Profit | US$39.61b |
| Other Expenses | US$35.37b |
| Earnings | US$4.24b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.40 |
| Gross Margin | 70.31% |
| Net Profit Margin | 7.52% |
| Debt/Equity Ratio | 2,001.6% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield263%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 02:48 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 48 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Luisa Hector | Berenberg |